ONC
$287.33
BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally.
Recent News
BeOne Medicines Ltd (ONC) Q4 2025 Earnings Call Highlights: Record Growth and Strategic Expansion
BeOne Medicines Ltd (ONC) reports robust revenue growth and outlines plans to solidify its leadership in oncology and immunology.
BeOne Medicines (ONC) Reports $1.5B Revenue for Q4, $1.1B from Lymphoma Treatment
BeOne Medicines AG (NASDAQ:ONC) is among the 12 best stocks to buy and hold for the next 2 years. On February 26, BeOne Medicines AG (NASDAQ:ONC) reported total global revenues of $1.5 billion for the fourth quarter of 2025 and $5.3 billion for 2026, increases of 33% and 40% from the prior-quarter and prior-year periods, […]
Is It Time To Reassess BeOne Medicines (ONC) After Strong Multi Year Share Price Gains
If you are trying to figure out whether BeOne Medicines' current share price reflects its underlying worth, the next sections will walk through what the numbers are really saying about value. The stock recently closed at US$352.23, with a 0.6% decline over 7 days, a 4.8% return over 30 days, a 13.2% return year to date and a 26.5% return over 1 year, while the 3 year and 5 year returns stand at 46.6% and 21.8% respectively. Recent news flow around BeOne Medicines has focused on its position...
Here's What Key Metrics Tell Us About BeOne Medicines Ltd. - Sponsored ADR (ONC) Q4 Earnings
The headline numbers for BeOne Medicines Ltd. - Sponsored ADR (ONC) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Bernstein Remains a Buy on BeOne Medicines AG (ONC)
BeOne Medicines AG (NASDAQ:ONC) is one of the High Growth International Stocks to Buy Now. On February 9, Rebecca Liang from Bernstein reiterated a Buy rating on the stock with a $414 price target. Earlier, on February 4, Barclays also reiterated a Buy rating on BeOne Medicines AG (NASDAQ:ONC) and raised the price target from […]